China factory Best quality High Purity 99% Peptide Retatrutide weight loss1

Retatrutide (LY3437943) acetate is a triple agonist peptide for the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R).

Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643, and 0.775 nM, respectively. It exhibits activity on mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191, and 0.794 nM, respectively.

In vivo, Retatrutide (LY3437943) acetate engages with GCGR and enhances glucose tolerance in an ipGTT by acting through GIP or GLP-1 receptors. Activation via the glucagon receptor by Retatrutide acetate leads to significant weight reduction and increased energy expenditure. Retatrutide acetate can be utilized in research related to obesity.

Retatrutide, LY3437943

CAS#: 2381089-83-2

Molecular Formula: C221H342N46O68

Molecular Weight: 4731.33

Sequence: H-Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-α-Me-Leu-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

Appearance: White Powder

Purity (HPLC): ≥99.0%

Single Impurity (HPLC): ≤1.0%

Sodium Content (HPLC): 5.0%-12.0%

Moisture Content (Karl Fischer): ≤10.0%

Peptide Content: ≥80.0%

Storage: Store at 2-8 degrees Celsius in a dry and cool place.

Packaging: 1g-1kg, plastic bottle

Intended Use: For scientific research purposes

Mechanism of Action and Molecular Structure of Retatrutide:

Triple Agonist Design
- GLP-1 receptor: Retatrutide delays gastric emptying, suppress appetite, and promote insulin secretion.
- GIP receptor: Retatrutide enhances insulin sensitivity and regulate central satiety signals.
- Glucagon receptor (GCGR): Retatrutide activates liver energy metabolism, promote lipolysis and glycogenolysis, and increase basal metabolic rate.
The triple synergistic effect increases energy consumption while reducing energy intake, significantly improving weight loss effects.

Indications and Efficacy:

★ Obesity Treatment:
In the Phase II clinical trial, patients in the highest dose group (12 mg) lost an average of 24.2% weight after 48 weeks, and some patients lost more than 30%.

★ Metabolic Dysfunction-Associated Fatty Liver Disease (MASLD):
Retatrutide can reduce liver fat content by 86%, and more than 85% of patients achieve regression of liver steatosis.

★ Type 2 Diabetes:
Significantly reduce glycated hemoglobin (HbA1c) and improve blood sugar control.

★ Potential Cardiovascular Benefits:
Animal studies have shown that it may indirectly protect cardiovascular health by improving blood pressure and heart function, but further clinical verification is needed.

Name: HELEN
WHATS：+852 6534 2130
Email：a17266234056@gmail.com